glyns answers and other things spoken about, page-7

I want to express my gratitude to 1S1 for being so considerate and take his time to get our questions answered !

We should consider having a permanent representative for these occasions like other company's shareholders do.

Thank you also to OBJ management for having achieved such clarity in their presentation. This is unmatched so far and answers many questions indeed.
It is Glyn's personality to be modest and conservative in his expactations, a characteristic I particularly appreciate.


To discuss all companies mentioned, it might make sense to start with those being the longest now in collaborations with OBJ.



UK FMCG

We finally are aware that we are dealing with 3 FMCGs here.
Our UK FMCG ( isn't this so enjoyable to omit FMCG1, 2, etc ? ) has concluded consumer acceptance studies, marketing assessment and is currently in discussions about
development.
What holders should realise here is the fact that the UK FMCG does not need to wait until actual launch to put dollar signs onto a contract.
If development discussions are coming to an end we could well see a material announcement there for that application.
Many biotech anns are putting milestone payments in place with staggered payments towards commercialisation.
I do get the distinct impression that we are nearing such a stage with several partners.


GSK
Nothing changed here from my view, we should see results of the in vivo studies early next year.
According to the graph in the presentation we are nearing efficiacy studies which are based on the in vivo results, indirectly offering us the information that we have successfully passed that stage already or are in the process of doing so.
This also opens the possibility that we see milestone payments mentioned once we pass the human trails.


USA FMCG

We now know that our Strategic Alliance FMCG is based in the US.
This company has pushed most aggressively forward and already enters prototype stage.
We are told that negotations with this company will be concluded within a few months.
This is most likely our first license deal in the making.
According to the time period spent on this program, I would think that a deal would arrive first half of 2012.
The preceeding announcement that negotiations were successful though should already rerate OBJ's shareprice.
I therefore would encourage fellow holders to see past the final commercialisation/ launch date as the time when
dollars are mentioned in the anns. We will not necessarily have to wait that long.
Usually 2 years prior to commercialisation a milestone contract should be in place, as mentioned above.

OBJ's pain patch

Interesting that this is listed under partnering companies.
If Tripeptofen is indeed our compound then PNO is that partner company, apart from other possible contributing partners as management left that option open.
I'm very pleased to see that we already hit concept testing for our own product.
Many here had anticipated this program to be in its infant shoes, far from it.
It also progresses quickly.
Who pays for this?
Interesting thoughts opening up there and probably content of many discussions to come.



The presentation is a very good read and we are definately in for some impressive shareprice movements over the next year.